Lubiprostone Capsule
Product Images NDC 70771-1763

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Lubiprostone (NDC 70771-1763). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Lifesciences Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

8 Mcg Label (D529a527 D19e 4cec A117 Ddc6cab4a8b1 01)

This is a medication package for Lubiprostone Capsules. It contains 60 soft gelatin capsules, each of which has 8mg of Lubiprostone and should be swallowed whole and not broken or chewed. The recommended dosage is provided in the package. The package is child-resistant and should be stored between 15°C to 30°C. The container should be kept tightly closed and protected from extreme temperatures. The drug should be kept out of the reach of children. The medication is manufactured by Zydus Ufesciences Ltd. in India.*

FDA Label Image

24 Mcg Label (D529a527 D19e 4cec A117 Ddc6cab4a8b1 02)

This is a description of Lubiprostone capsules, which contain 24mg of the drug per 50g gel capsule. The usual dosage of the drug is provided in the package insert or complete prescribing information. The capsules should be swallowed whole and not broken, agitated, or chewed. The package is child-resistant and should be stored between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). The container should be kept tightly closed and protected from extreme temperatures. The manufacturer is Zydus Sciences Ltd. based in Ahmedabad, India. It is recommended to keep this and all drugs out of the reach of children.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.